Filtered By:
Condition: Fatty Liver Disease (FLD)
Nutrition: High Fat

This page shows you your search results in order of date.

Order by Relevance | Date

Total 17 results found since Jan 2013.

Dengyinnaotong attenuates atherosclerotic lesions, gut dysbiosis and intestinal epithelial barrier impairment in the high fat diet-fed ApoE < sup > -/- < /sup > mice
CONCLUSIONS: Our work provides novel preclinical evidence that underpins the multifaceted effects of DYNT in the control of atherosclerosis.PMID:37453620 | DOI:10.1016/j.jep.2023.116916
Source: Atherosclerosis - July 15, 2023 Category: Cardiology Authors: Minqi Xiong Zilong Zhang Jingang Cui Xiaoye Du Yu Chen Teng Zhang Source Type: research

Suppression of nitric oxide synthase aggravates non-alcoholic steatohepatitis and atherosclerosis in SHRSP5/Dmcr rat via acceleration of abnormal lipid metabolism
CONCLUSIONS: NOS inhibition simultaneously aggravates NASH and atherosclerosis via hepatic lipid and cholesterol metabolism.PMID:35819592 | DOI:10.1007/s43440-022-00380-1
Source: Atherosclerosis - July 12, 2022 Category: Cardiology Authors: Ikumi Sato Shusei Yamamoto Mai Kakimoto Moe Fujii Koki Honma Shota Kumazaki Mami Matsui Hinako Nakayama Sora Kirihara Shang Ran Shinichi Usui Ryoko Shinohata Kazuya Kitamori Satoshi Hirohata Shogo Watanabe Source Type: research

Akebia saponin D ameliorates metabolic syndrome (MetS) via remodeling gut microbiota and attenuating intestinal barrier injury
Biomed Pharmacother. 2021 Feb 27;138:111441. doi: 10.1016/j.biopha.2021.111441. Online ahead of print.ABSTRACTMetabolic syndrome (MetS) is a complex, multifactorial disease which lead to an increased risk of cardiovascular disease, type 2 diabetes, and stroke. However, selective, and potent drugs for the treatment of MetS are still lacking. Previous studies have found that Akebia saponin D (ASD) has beneficial effects on metabolic diseases such as obesity, atherosclerosis, and non-alcoholic fatty liver disease (NAFLD). Therefore, our study was designed to determine the effect and mechanism of action of ASD against MetS in ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - March 2, 2021 Category: Drugs & Pharmacology Authors: Song Yang Ting Hu He Liu Ya-Li Lv Wen Zhang Han Li Lingling Xuan Li-Li Gong Li-Hong Liu Source Type: research

Molecules, Vol. 26, Pages 302: Protective Effects of Polyphenol Enriched Complex Plants Extract on Metabolic Dysfunctions Associated with Obesity and Related Nonalcoholic Fatty Liver Diseases in High Fat Diet-Induced C57BL/6 Mice
Conclusions: The results of this study demonstrated that the herbal complex is an effective herbal formulation in the attenuation of obesity and obesity-induced metabolic dysfunction including NAFLD in HFD-induced mouse model.
Source: Molecules - January 8, 2021 Category: Chemistry Authors: Ahtesham Hussain Jin Sook Cho Jong-Seok Kim Young Ik Lee Tags: Article Source Type: research

Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway.
In this study, Sprague-Dawley rats were fed a high fat diet (HFD) for 5 weeks to establish a hyperlipidaemia model; then, the rats were orally administered KLX (20, 40, and 80 mg kg-1·d-1) or atorvastatin calcium (AT, 10 mg kg-1·d-1) once a day for 2 weeks. KLX had prominent effects on reducing blood lipids, hepatic lipid accumulation, body weight and the ratio of liver weight/body weight. Furthermore, KLXdramatically reduced the total cholesterol (TC) and triglyceride (TG) levels and lipid accumulation in a HepG2 cell model of dyslipidaemia induced by 1 mmol/L oleic acid (OA). KLX may decrease lipid levels by phosphoryl...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - November 14, 2020 Category: Drugs & Pharmacology Authors: Li X, Hu X, Pan T, Dong L, Ding L, Wang Z, Song R, Wang X, Wang N, Zhang Y, Wang J, Yang B Tags: Biomed Pharmacother Source Type: research

Effects of surface-deacetylated chitin nanofibers on non-alcoholic steatohepatitis model rats and their gut microbiota.
Abstract Nonalcoholic steatohepatitis (NASH), a more advanced form of nonalcoholic fatty liver disease (NAFLD), is associated with increased cardiovascular and liver-related mortality. Stroke-prone spontaneously hypertensive rats (SHRSP5/Dmcr) that are fed a high-fat and high-cholesterol diet develop hepatic lesions that are similar to those observed in human NASH pathology. We investigated the hepatic protective and antioxidant effects of surface-deacetylated chitin nanofibers (SDACNFs) that were administered to SHRSP5/Dmcr rats for 8 weeks. The administration of SDACNFs (80 mg/kg/day) resulted in a significa...
Source: International Journal of Biological Macromolecules - July 18, 2020 Category: Biochemistry Authors: Goto M, Iohara D, Michihara A, Ifuku S, Azuma K, Kadowaki D, Maruyama T, Otagiri M, Hirayama F, Anraku M Tags: Int J Biol Macromol Source Type: research

Increasing Upstream Chromatin Long –Range Interactions May Favor Induction of Circular RNAs in LysoPC-Activated Human Aortic Endothelial Cells
We examined the sponging potential of all significantly changed circRNAs using the CircInteractome database (Montefiori et al., 2018), recording two miRNAs with four or more predicted binding sites in a single circRNA transcript, a threshold above which meaningful sponging activity is likely to occur Memczak et al. (2013). Another four significantly changed circRNAs are experimentally shown to sponge miRNAs (Dudekula et al., 2016; Chen et al., 2017; Yan et al., 2017; Wang et al., 2018), for six total circRNAs with miRNA sponging activity including miR125, miR143, miR1272, miR153, miR515-5p, and miR196a-5p (Table 4). In Fig...
Source: Frontiers in Physiology - April 17, 2019 Category: Physiology Source Type: research

The Discovery and Development of Liraglutide and Semaglutide
We describe one such approach, albumin binding, and explain how it was applied in the development of the human GLP-1 analog liraglutide once daily and, subsequently, semaglutide once weekly. The pharmacology of these two long-acting GLP-1 analogs, in terms of improving glycemic control, reducing body weight and decreasing cardiovascular (CV) risk, is also reviewed, together with some novel biology. In addition, we describe the importance of accurate target (GLP-1 receptor) tissue expression analysis. Now an established class of agents, GLP-1-based therapies represent a significant advance in the treatment of T2D. All curr...
Source: Frontiers in Endocrinology - April 11, 2019 Category: Endocrinology Source Type: research